Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045162 · ClinicalTrials.gov registry record · Phase 3
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 671
- Enrollment target
NCT00045162: Completed Phase 3 study, sponsored by SWOG Cancer Research Network.
NCT00045162 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 671 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045162, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 671 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin combined with irinotecan is more effective than cisplatin combined with etoposide in treating extensive-stage small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin combined with either irinotecan or etoposide in treating patients who have extensive-stage small cell lung cancer.
Primary Outcome
Overall survival was defined as the duration between the date of randomization( enrollment) and the date of death due to any cause. Patients last known to be alive were censored at the date of last contact.
Interventions
- DRUG cisplatin
- DRUG etoposide
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 671 participants |
| Start Date | 2002-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
What the finished NCT00045162 record still lists
NCT00045162 is an interventional study that assigns participants to a tested intervention. The registered 671 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00045162 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00045162 about?
NCT00045162 is a clinical study titled "S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin combined with irinotecan is more effective than cisplatin combined with etoposide in t...
What is the current status of trial NCT00045162?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 671 participants. The study started on 2002-11. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00045162?
The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00045162?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00045162's enrollment target sits among peer trials
671 544th of 2000 higher than 1,455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07184944 · 671 participants · Phase 3
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- NCT07185009 · 671 participants · Phase 3
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- NCT05452031 · 672 participants · NA
A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers
- NCT05493254 · 672 participants · NA
Enhancing Smoking Cessation Via Telehealth Options in Primary Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia